logo-loader
RNS
viewMaxCyte Inc

MaxCyte to Host Capital Markets Day Today

/**/ h1{margin-right:0cm;margin-left:0cm;text-align:left;line-height:normal;font-size:24.0pt;font-family:"Times New Roman","serif";font-weight:bold;}p{margin-top:3.75pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:0cm;text-align:justify;line-height:13.5pt;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .cg{size:595.3pt 841.9pt;margin:63.8pt 72.0pt 56.75pt 72.0pt;}div.cg{}p.dw{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: center}span.du{font-size:14.0pt;font-family:"Calibri","sans-serif"}p.dx{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";text-align: center}span.ds{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.dy{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";line-height:112%}span.dq{font-size:11.0pt; line-height:112%;font-family:"Calibri","sans-serif"}span.do{font-size:11.0pt;line-height:112%;font-family: "Calibri","sans-serif"}span.dn{font-size:11.0pt;line-height:112%;font-family:"Calibri","sans-serif"; color:black} span.dm{font-size:11.0pt; line-height:112%;font-family:"Calibri","sans-serif";color:black}p.dz{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 112%}p.ea{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";text-indent:-18.0pt;line-height:112%}span.dk{font-size:11.0pt;line-height:112%;font-family:Symbol;color:black}p.eb{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-div: italic; line-height: 112%}span.dh{font-size: 11.0pt;line-height:112%;font-family:"Calibri","sans-serif"}p.ec{margin:0cm;margin-bottom:.0001pt;text-align:left;line-height:normal;text-autospace:none;font-size:12.0pt;font-family:"Bradley Hand ITC";color:black;font-weight: bold; line-height: 150%; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.dg{font-size:11.0pt;line-height: 150%;font-family:"Calibri","sans-serif"}p.ed{margin:0cm;margin-bottom:.0001pt;text-align:left;line-height:normal;text-autospace:none;font-size:12.0pt;font-family:"Bradley Hand ITC";color:black;font-weight: bold; line-height: 112%; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.de{font-size:11.0pt;line-height: 112%;font-family:"Calibri","sans-serif"} p.ee{margin:0cm;margin-bottom:.0001pt;text-align:left;line-height:normal;text-autospace:none;font-size:12.0pt;font-family:"Bradley Hand ITC";color:black;text-align:justify;line-height:112%;text-autospace: ideograph-numeric ideograph-other}span.dc{font-size:11.0pt;line-height:112%;font-family:"Calibri","sans-serif"}p.ef{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";line-height:150%}span.da{font-size:11.0pt; line-height:150%;font-family:"Calibri","sans-serif"}p.eg{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";margin-left:-4.5pt;line-height:150%}span.cy{font-size:11.0pt;line-height:150%;font-family:"Calibri","sans-serif"}table.eh{width:472.5pt;margin-left:-10.8pt;border-collapse:collapse}tr.cs{height:14.05pt}td.cu{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt}p.ei{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 150%} span.cv{font-family:"Calibri","sans-serif"}td.ct{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt}tr.cn{height:92.7pt}td.cp{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:92.7pt}p.ej{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-div: italic; font-weight: bold; line-height: 150%}span.cr{font-size: 11.0pt;line-height:150%;font-family:"Calibri","sans-serif"}td.co{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:92.7pt}tr.ci{height:101.25pt}td.ck{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:101.25pt}span.cm{font-size:11.0pt; line-height:150%;font-family:"Calibri","sans-serif";color:black} span.cl{font-family: "Calibri","sans-serif"}td.cj{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:101.25pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";} /**/
RNS Number : 1593F
MaxCyte, Inc.
11 July 2019
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

MaxCyte to Host Capital Markets Day Today

 

 

Gaithersburg, Maryland - 11 July 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, is today hosting a Capital Markets Day for institutional investors and analysts in London.

 

Doug Doerfler, Chief Executive Officer, will host the event with other members of Maxcyte's  commercial, medical and financial leadership team and leading key opinion leaders from the fields of cell and gene therapy and immuno-oncology.  The event will include presentations on MaxCyte's Flow Electroporation® technology, which underlies MaxCyte's 70+ partnered programme licenses, and the differentiation of its CARMA™ platform, as well as a live demonstration of its recently announced ExPERT™ family of instruments.

 

The agenda follows:

·    Welcome and Introduction - Doug Doerfler, President & Chief Executive Officer

·    Customer Focus / Product and Applications Innovation - Brad Calvin, EVP, Global Commercial Operations

·    Enabling Technologies: Role of Flow Electroporation - John McCafferty, PhD, Founder and Chief Executive Officer, IONTAS

·    Immuno-Oncology Landscape and CARMA Differentiation - Christina M. Annunziata, MD, PhD, Principal Investigator and Clinical Director, National Cancer Institute

·    CARMA - the Clinical Pathway and Future Opportunities - Claudio Dansky Ullmann, MD, Chief Medical Officer

·    Financial Overview - Ron Holtz, Chief Financial Officer

·    Closing and Questions - Doug Doerfler, President & Chief Executive Officer

 

Event details

The meeting will be held at the London Stock Exchange, 10 Paternoster Row, London, EC4M 7LS. The event will start at 15:00 BST, and will conclude with an informal drinks and networking session from approximately 17:30 BST.

 

A video recording of all presentations will be available on the MaxCyte website shortly after the event.

 

Please contact [email protected] if you would like to attend today's event and have not already registered.

 

No new price sensitive information will be disclosed on this day. A trading update will be announced on 17 July 2019.

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered programme licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250M. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 


+44 (0)20 7260 1000

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

[email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLFFFIDEIILIA

Quick facts: MaxCyte Inc

Price: 120

Market: AIM
Market Cap: £68.87 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18